NasdaqGS:IDYABiotechs
A Look At IDEAYA Biosciences (IDYA) Valuation After Darovasertib OptimUM-02 And Pipeline Updates
IDEAYA Biosciences (IDYA) is back in focus after reporting OptimUM-02 data showing longer median progression-free survival for its lead melanoma drug, darovasertib, and signaling plans for an NDA filing and broader pipeline expansion.
See our latest analysis for IDEAYA Biosciences.
IDEAYA's recent darovasertib update comes after a choppy few months, with the share price up 4.7% over the last day and 2.6% over the past week, but down around 12% year to date. The 1 year total shareholder return...